NCM · Biotechnology

AVTX (AVTX) Stock

$18.97 +2.87% NCM: AVTX Healthcare

Valuation

MetricValue
Price$18.97
Market Cap$214.25M
P/E Ratio-2.79
P/B Ratio2.21
P/S Ratio3158.31
EPS (TTM)$-5.84
52-Week High$24.27
52-Week Low$4.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-93.98%
ROA-67.24%
ROCE-87.95%
Gross Margin71.19%
Operating Margin-1341.64%
Net Margin-1436.27%
Debt/Equity0.03
Current Ratio8.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$5.0M$18.0M$2.0M$0$0
Operating Profit$-82.0M$-37.0M$-27.0M$-69.0M$-73.0M
Net Profit$-84.0M$-42.0M$-32.0M$-35.0M$-78.0M
EPS$-2330.66$-1062.65$-113.58$-3.26$-5.84
Op Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$80.0M$33.0M$21.0M$151.0M$116.0M
Total Liabilities$57.0M$44.0M$14.0M$18.0M$33.0M
Cash$55.0M$13.0M$7.0M$135.0M$16.0M
Borrowings$33.0M$20.0M$1.0M$1.0M$2.0M

Latest News

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum GlobeNewswire · Jul 7, 2026 Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed Simply Wall St. · Jun 30, 2026 Sector Update: Healthcare Stocks Mixed Premarket Friday MT Newswires · Jun 26, 2026 Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes MT Newswires · Jun 26, 2026 Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-71.0M$-27.0M$-31.0M$-49.0M$-51.0M
Investing Cash Flow$0$0$0$0$-82.0M
Financing Cash Flow$2.0M$0$0$60.0M$-1.0M
Net Cash Flow$36.0M$-41.0M$-6.0M$127.0M$-119.0M
Free Cash Flow$-71.0M$-27.0M$-31.0M$-49.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-32.03%
Quick Ratio7.66
Interest Coverage—
Return 1Y275.92%
Return 3Y-76.88%
Return 5Y-99.78%

Ownership

Insiders Held1.73%
Institutions Held76.13%
Institutions Float Held77.47%
Institutional HolderSharesReport Date
FMR, LLC2,879,4812026-03-31
T. Rowe Price Investment Management, Inc.2,162,6842026-03-31
Caligan Partners, LP1,635,0232026-03-31
BVF Inc.1,632,8452026-03-31
Avoro Capital Advisors LLC1,410,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
BDTX $1.76 +1.45% -1.48 $100.56M 0.00%
CHRS $1.27 +0.40% -2.21 $155.46M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%

About AVTX

AVTX is led by CEO Garry A. Neil, employs 23 people, headquartered in US, publicly traded since 2015.

AVTX stock trades at $18.97 with a market capitalization of $214.25M. The stock is valued at a price-to-earnings (P/E) ratio of -2.79, price-to-book of 2.21, price-to-sales of 3158.31. Over the past 52 weeks the stock has ranged between $4.50 and $24.27, and currently trades 21.8% below its 52-week high.

On profitability, AVTX generates a return on equity (ROE) of -93.98%, return on capital employed of -87.95%, an operating margin of -1341.64%, a net profit margin of -1436.27%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides